Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2018100557) 5-[[4-[2-[5-(1-HYDROXYETHYL)PYRIDIN-2-YL]ETHOXY]PHENYL]METHYL]-1,3-THIAZOLIDINE- 2,4-DIONE FOR TREATING NONALCOHOLIC FATTY LIVER DISEASE
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2018/100557 International Application No.: PCT/IB2017/057587
Publication Date: 07.06.2018 International Filing Date: 01.12.2017
Chapter 2 Demand Filed: 01.10.2018
IPC:
A61K 31/4439 (2006.01) ,A61P 1/16 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
435
having six-membered rings with one nitrogen as the only ring hetero atom
44
Non-condensed pyridines; Hydrogenated derivatives thereof
4427
containing further heterocyclic ring systems
4439
containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
1
Drugs for disorders of the alimentary tract or the digestive system
16
for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
Applicants:
MINORYX THERAPEUTICS S.L. [ES/ES]; TechnoCampus Mataró-Maresme Av. Ernest Lluch 32, TCM3 E-08302 Mataró Barcelona, ES
Inventors:
PIZCUETA LALANZA, Maria Pilar; ES
MARTINELL PEDEMONTE, Marc; ES
Priority Data:
16382584.701.12.2016EP
Title (EN) 5-[[4-[2-[5-(1-HYDROXYETHYL)PYRIDIN-2-YL]ETHOXY]PHENYL]METHYL]-1,3-THIAZOLIDINE- 2,4-DIONE FOR TREATING NONALCOHOLIC FATTY LIVER DISEASE
(FR) 5-[[4-[2-[5-(1-HYDROXYÉTHYL)PYRIDIN-2-YL]ÉTHOXY]PHÉNYL]MÉTHYL]-1,3-THIAZOLIDINE-2,4-DIONE POUR LE TRAITEMENT D'UNE STÉATOSE HÉPATIQUE NON ALCOOLIQUE
Abstract:
(EN) The present disclosure relates to a method of treating or preventing nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, a chronic granulomatous disorder, a polycystic ovary syndrome, a thyroid carcinoma, a thyroid autoimmune disorder, a pituitary adenoma, atherosclerosis, hypertension, a skin disease, an inflammation and autoimmune disease, and an inflammatory respiratory disease by administering 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione to a subject in need thereof. The disclosure also relates to 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione for use in a pharmaceutical composition or in the manufacture of a medicament for the treatment or prevention of nonalcoholic fatty liver disease or nonalcoholic steatohepatitis.
(FR) La présente invention concerne une méthode de traitement ou de prévention d'une stéatose hépatique non alcoolique, d'une stéatohépatite non alcoolique, d'un trouble granulomateux chronique, d'un syndrome des ovaires polykystiques, d'un carcinome de la thyroïde, d'un trouble auto-immun de la thyroïde, d'un adénome hypophysaire, d'athérosclérose, d'hypertension, d'une maladie cutanée, d'une inflammation et d'une maladie auto-immune, et d'une maladie respiratoire inflammatoire par l'administration de 5-[[4-[2-[5-(1-hydroxyéthyl))pyridin-2-yl]éthoxy]phényl]méthyl]-1,3-thiazolidine-2,4-dione à un sujet en ayant besoin. L'invention concerne également la 5-[[4-[2-[5-(1-hydroxyéthyl))pyridin-2-yl]éthoxy]phényl]méthyl]-1,3-thiazolidine-2,4-dione pour une utilisation dans une composition pharmaceutique ou dans la fabrication d'un médicament pour le traitement ou la prévention de la stéatose hépatique non alcoolique ou de la stéatohépatite non alcoolique.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)